跳转至内容
Merck
CN

1672745

USP

氨甲环酸

United States Pharmacopeia (USP) Reference Standard

别名:

反-4-(氨基甲基)环己烷羧酸, AMCA, 反-4-(氨基甲基)环已基羧酸, 抗血纤溶环酸, 氨甲基环己酸, 氨甲环酸

登录 查看组织和合同定价。

选择尺寸


关于此项目

线性分子式:
H2NCH2C6H10CO2H
化学文摘社编号:
分子量:
157.21
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
2207452
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

氨甲环酸, United States Pharmacopeia (USP) Reference Standard

InChI

1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-

SMILES string

NC[C@H]1CC[C@@H](CC1)C(O)=O

InChI key

GYDJEQRTZSCIOI-LJGSYFOKSA-N

grade

pharmaceutical primary standard

API family

tranexamic acid

manufacturer/tradename

USP

mp

>300 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... PLG(5340)

正在寻找类似产品? 访问 产品对比指南

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Application

Tranexamic acid USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Tranexamic Acid Tablets
  • Tranexamic Acid Injection

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Julian Gilbody et al.
The Journal of arthroplasty, 29(4), 681-684 (2013-10-08)
The efficaciousness of topical tranexamic acid use at the end of knee arthroplasty surgery to reduce blood loss and transfusion requirements has previously been shown. The aim of this study was to retrospectively assess the effectiveness of topical tranexamic acid
Anthony E Pusateri et al.
Shock (Augusta, Ga.), 39(2), 121-126 (2012-12-12)
A recent large civilian randomized controlled trial on the use of tranexamic acid (TXA) for trauma reported important survival benefits. Subsequently, successful use of TXA for combat casualties in Afghanistan was also reported. As a result of these promising studies
Michalis Panteli et al.
The Knee, 20(5), 300-309 (2013-07-03)
To examine the safety and efficacy of topical use of tranexamic acid (TA) in total knee arthroplasty (TKA). An electronic literature search of PubMed Medline; Ovid Medline; Embase; and the Cochrane Library was performed, identifying studies published in any language
V Pundir et al.
Rhinology, 51(4), 291-297 (2013-11-22)
The role of tranexamic acid in patients undergoing endoscopic sinus surgery (ESS) is not clearly defined. The aim of our study is to systematically review the existing evidence on the role of tranexamic acid in patients undergoing ESS. Systematic search
K Ker et al.
The British journal of surgery, 100(10), 1271-1279 (2013-07-11)
Tranexamic acid (TXA) reduces blood transfusion in surgery but the extent of the reduction in blood loss and how it relates to the dose of TXA is unclear. A systematic review of randomized trials was performed. Data were extracted on

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持